SLC6A2 and Cognitive impairment: Based on the monoamine hypothesis for cognitive impairments, our approach lends further support for pursuing the development of allosteric modulators of DAT and NET as a therapeutic approach for mitigating Tat-induced neurocognitive disorders in the context of drug abuse in HIV+ patients.